ICMJE Medical Writing Guidelines: What They Are and How to Follow Them

Every researcher who has prepared a biomedical manuscript has, at some point, encountered the phrase “in accordance with ICMJE guidelines.” But what those guidelines actually require, across authorship, structure, disclosure, data sharing, and ethics, is far less well understood than the frequency of that phrase suggests. 

Medical writing errors that lead to desk rejection, major revision, or post-publication retraction almost always trace back to a gap between what the ICMJE requires and what the author submitted.

This guide covers the full scope of ICMJE medical writing guidelines: who qualifies as an author, how to structure a manuscript, how to report clinical trial data correctly, what data transparency obligations now require, how GPP4 relates to clinical trial writing, and how to navigate the ethical questions that peer reviewers and editors scrutinise most closely. 

Whether your manuscript is a randomised controlled trial, a systematic review, a case report, or a laboratory study, these principles apply directly to your work.

Preparing a manuscript that meets these standards is demanding. Researchers working on their medical editing and writing submissions often find that a second expert review of structure, terminology, and compliance catches issues that close reading alone does not.

What Is the ICMJE? Authority, History, and Scope

The International Committee of Medical Journal Editors (ICMJE) is an informal working group of major biomedical journal editors that first convened in Vancouver, British Columbia, in 1978. 

The resulting document, originally called the Vancouver Guidelines and now formally titled the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, sets the baseline standards that the majority of peer-reviewed biomedical journals around the world require authors to meet.

The ICMJE’s founding members included editors from the New England Journal of Medicine, The Lancet, JAMA, BMJ, Annals of Internal Medicine, and several other leading journals. 

Today, thousands of journals globally either formally adopt ICMJE recommendations or cite alignment with them in their author guidelines. When a journal states that it follows “uniform requirements,” it is referring to the ICMJE framework.

The scope of ICMJE recommendations covers every stage of the manuscript lifecycle: the research conduct that precedes writing, the authorship and contribution of individuals named on the paper, the manuscript structure and content, the disclosure of funding and conflicts of interest, the handling of peer review, and the ethics of publication. 

It is an integrated ethics and standards framework for the entire scholarly publication process.

Key ICMJE Member Journals

The Four ICMJE Authorship Criteria – Who Can Be Named as an Author

The most frequently misunderstood aspect of ICMJE guidelines is the authorship standard. ICMJE requires that every named author on a biomedical manuscript meet all four of the following criteria. Meeting one, two, or three criteria is not sufficient for authorship.

Contributors who do not meet all four criteria should not be listed as authors. Their contributions should instead be acknowledged in an Acknowledgements section. This includes individuals who provided funding, recruited patients, performed statistical analysis without contributing to interpretation, or supplied laboratory materials. 

The ICMJE is explicit that “ghost authorship” (unnamed contributors who drafted the paper) and “gift authorship” (named authors who made no qualifying contribution) are both violations of publication ethics.

Journals increasingly ask authors to complete a CRediT (Contributor Roles Taxonomy) statement specifying each author’s contribution. CRediT lists 14 standardised roles covering conceptualisation, data curation, formal analysis, funding acquisition, investigation, methodology, project administration, resources, software, supervision, validation, visualisation, and writing. 

This system does not replace ICMJE authorship criteria; it supplements them by documenting how each qualifying author contributed.

Ghost Authorship and Gift Authorship

Ghost authorship occurs when a medical writer or researcher who drafted a substantial portion of the manuscript is not named as an author. This is a recognised ethical problem in pharmaceutical-sponsored research, where contracted medical writers prepare manuscripts that are then submitted under physician or researcher authors who had limited involvement. 

The ICMJE position is that anyone who meets the four authorship criteria must be named; a medical writer who meets those criteria cannot ethically be omitted.

Gift authorship occurs in the opposite direction: a senior researcher, department head, or collaborator is named as an author as a courtesy or in exchange for access to resources, despite not meeting the criteria. Both practices are research misconduct under ICMJE guidelines and are increasingly targeted by journal editors and research integrity investigations.

ICMJE vs GPP4 – Understanding Both Frameworks in Clinical Writing

Researchers working in pharmaceutical, clinical, and regulatory contexts often need to understand how ICMJE guidelines interact with GPP4 (Good Publication Practice 4th edition), a separate framework developed by ISMPP (the International Society for Medical Publication Professionals) specifically for industry-sponsored clinical research.

GPP4, published in 2022, addresses the specific ethical and transparency challenges that arise when clinical trial data is published by authors who have industry funding relationships. While ICMJE guidelines apply universally to all biomedical manuscripts, GPP4 provides more detailed operational guidance for publication planning in clinical research settings.

GPP4 compliance in clinical trial reporting is particularly relevant for researchers who receive industry funding, who are involved in sponsored clinical studies, or whose manuscripts include data generated by pharmaceutical or device companies. 

Journals covering clinical pharmacology, oncology, cardiology, and related fields are most likely to scrutinise GPP4 alignment. Understanding both frameworks is essential for clinical researchers who need to ensure their manuscript meets the expectations of both the publishing journal and the sponsoring organisation.

How to Write a Medical Research Manuscript – ICMJE Structure (IMRAD)

The ICMJE does not prescribe a single rigid structure for all biomedical manuscripts, but the IMRAD format (Introduction, Methods, Results, and Discussion) is the standard for original research. Each section has defined content expectations that editors and peer reviewers assess against these guidelines. Understanding copy writing vs structural editing is also important, as structural editing focuses on improving the organization and flow of a manuscript, while copy writing refines clarity, grammar, and readability without changing the overall structure.

Introduction

The Introduction should establish the scientific question being addressed, the gap in existing knowledge that your study fills, and the specific objective or hypothesis of the study. 

ICMJE guidance is that the Introduction should be brief and should not review literature extensively; that function belongs in the Discussion. Each claim in the Introduction must be supported by a citation. The final sentence typically states the study aim or hypothesis explicitly.

Methods

The Methods section is the most technically demanding part of a biomedical manuscript under ICMJE standards. It must contain enough detail to allow replication of the study. Required elements include:

• Study design and setting (with dates of data collection)
• Participant selection criteria (inclusion and exclusion criteria for clinical studies)
• Interventions or exposures, described in sufficient detail for replication
• Primary and secondary outcomes, defined before data collection where applicable
• Statistical methods, including software, version, and specific tests used
• Ethical approval details (committee name, reference number, declaration of informed consent)
• Clinical trial registration number (mandatory for clinical trials)
• Data availability statement

For clinical trials, the Methods section must also confirm compliance with the applicable reporting guideline, most commonly CONSORT for randomised controlled trials.

Results

The Results section presents findings without interpretation. Data should be presented with appropriate measures of precision and uncertainty (confidence intervals, p-values, effect sizes). Tables and figures must be self-explanatory, with complete headings and footnotes. ICMJE guidance requires that numerical data in the text and in tables be consistent, a common source of peer reviewer corrections.

Discussion

The Discussion interprets the results in the context of existing literature, addresses limitations explicitly, and draws conclusions that are proportionate to the evidence. ICMJE guidelines require that the Discussion not repeat the Results section. Limitations must be described honestly; failure to acknowledge limitations is a common basis for peer reviewer criticism. Conclusions must not overstate what the data demonstrate.

Abstract

Most journals require a structured abstract with clearly labelled sections (Background, Methods, Results, Conclusions). The abstract must accurately reflect the manuscript body. ICMJE guidelines warn against selective reporting in the abstract, reporting positive findings while omitting neutral or negative results.

For researchers preparing manuscripts for specific journals, the requirements around structure, word counts, and section labelling vary considerably. Professional manuscript formatting support ensures that the structural presentation matches journal-specific requirements alongside ICMJE baseline standards.

CONSORT Diagram and Reporting Requirements for Clinical Trials

The CONSORT (Consolidated Standards of Reporting Trials) framework is the primary reporting standard for randomised controlled trials (RCTs) and is endorsed by the ICMJE, the WHO, and thousands of journals globally. CONSORT defines what information must appear in a clinical trial manuscript and includes a 25-item checklist and a flow diagram that tracks participant progress through the trial.

The CONSORT Flow Diagram – What Must Be Shown

The CONSORT flow diagram is not optional for RCT submissions to ICMJE-aligned journals. It must document the following four stages:

The CONSORT checklist must typically be submitted alongside the manuscript as a separate document, with page numbers indicating where each required element appears in the paper. Journals that are ICMJE members or that endorse CONSORT will check the checklist against the submitted manuscript; inconsistencies are a common basis for revision requests.

CONSORT Extensions

CONSORT has been extended to cover specific trial types that the original framework did not address:

• CONSORT-EHEALTH for trials of digital health interventions
• CONSORT-PRO for trials using patient-reported outcomes
• CONSORT for pilot and feasibility trials
• Cluster CONSORT for cluster-randomised trials
• CONSORT-Harms for reporting of adverse events

Authors should identify which extension applies to their trial and comply with both the core CONSORT checklist and the relevant extension.

Other Reporting Guidelines Endorsed by ICMJE

The EQUATOR Network maintains a comprehensive library of reporting guidelines for all major health research study types. Using the correct reporting guideline is a prerequisite for submission to most indexed biomedical journals, and peer reviewers routinely check compliance.

Biomedical Journal Formatting Standards

Beyond the structural requirements of IMRAD and reporting guidelines, ICMJE guidelines cover a range of formatting standards that apply to the manuscript document itself. These standards are designed to ensure consistency, verifiability, and clarity across submissions.

References and Citations

The ICMJE specifies that references must be numbered consecutively in the order they first appear in the text. Reference style follows the NLM (National Library of Medicine) format, commonly known as Vancouver style. Key requirements include:

• Journal article references must include: all authors (or first three authors followed by “et al.” for more than six), article title, abbreviated journal name (following NLM abbreviations), year, volume, issue, and inclusive page numbers
• For online resources, the URL and date of access must be included
• DOI numbers should be included where available
• Only sources cited in the text should appear in the reference list
• Unpublished work and personal communications require author permission and should be cited sparingly
• Reference management software should be checked against the NLM style specification; automatic formatting is not always accurate

Abbreviations

Abbreviations must be defined at first use in the abstract and again at first use in the text. Standard units and abbreviations (SI units, established anatomical and biochemical terms) need not be defined. A list of abbreviations is typically required as a separate section. Excessive use of non-standard abbreviations is a common editorial complaint and impedes peer review.

Tables and Figures

Tables must be self-explanatory with a complete title and any necessary footnotes. All abbreviations used in tables must be defined in a footnote, even if defined in the text. Figures require a caption that allows the figure to be understood independently of the text. Statistical output in figures must include sample sizes, effect sizes, and measures of uncertainty.

Units of Measurement

ICMJE guidelines specify the use of SI (International System of Units) for all measurements. Where non-SI units are used in a particular clinical context (such as mmHg for blood pressure or mEq/L in some biochemistry contexts), SI equivalents should be provided parenthetically. Consistent unit use across tables, figures, and text is checked during peer review.

Researchers who need their manuscripts aligned to the precise formatting specifications of a target journal alongside these ICMJE baseline standards will find that professional journal article editing support addresses both layers simultaneously, reducing the risk of technical rejection.

Medical Data Transparency Guidelines

Data transparency in medical publishing has become one of the most actively evolving areas of ICMJE policy. The 2016 update to ICMJE recommendations introduced a requirement that authors of manuscripts reporting clinical trial results include a statement on data sharing. This requirement has been progressively strengthened.

What the ICMJE Data Sharing Policy Requires

Since 2019, the ICMJE has required that manuscripts reporting clinical trials include a data sharing statement addressing the following:

• Whether individual participant data (IPD) will be shared
• What specific data will be shared
• When the data will be available (from what date)
• For how long the data will be available
• By what access criteria (application process, open access, restricted)
• What supporting documents will be shared (protocol, statistical analysis plan, informed consent form)
• Where the data will be available (specific repository or contact)

Clinical trial registration is a prerequisite for data sharing compliance: the ICMJE requires that clinical trials be registered before enrolment in a WHO International Clinical Trials Registry Platform-approved primary registry. The registration record must include a commitment to data sharing, and the data sharing statement in the manuscript must be consistent with the trial registration.

Approved Data Repositories

When data cannot be shared (for reasons of participant privacy, legal restriction, or institutional embargo), the data sharing statement must explain why. “Data are available on reasonable request” is not acceptable as a substitute for a defined access pathway; the ICMJE and many journals now require a specific contact address, repository link, or application procedure.

Ethical Issues in Medical Publishing

Ethical compliance is not a peripheral concern in ICMJE medical writing guidelines; it is their structural foundation. Journals that align with ICMJE recommendations check manuscripts for a range of ethical requirements, and failures at this level result not just in rejection but in post-publication retraction and potential regulatory consequences.

Research Ethics Approval

Every manuscript reporting research involving human participants must include a statement confirming that the study was approved by an appropriate research ethics committee (also called an institutional review board, or IRB). The statement must include the name of the committee and the reference number of the approval. The Methods section must also state that informed consent was obtained from participants, or explain why it was waived.

Conflict of Interest Disclosure

The ICMJE requires that all authors complete a conflict of interest disclosure using the ICMJE’s standardised Conflict of Interest Disclosure Form. Disclosable interests include financial relationships (payments, equity, grants, royalties, consulting fees), non-financial relationships (personal relationships, positions of authority, intellectual commitments), and organisational affiliations. 

The disclosure must cover the period of the work and any ongoing relationships. Journals typically require completed forms to be submitted alongside the manuscript.

Failure to disclose relevant conflicts of interest is one of the most common bases for post-publication correction and retraction. High-profile examples in cardiology, oncology, and psychiatry have shaped a strict editorial culture around disclosure. When in doubt, disclose; journals handle incomplete disclosures more charitably than undisclosed conflicts discovered post-publication.

Plagiarism and Duplicate Publication

ICMJE guidelines prohibit simultaneous submission of the same manuscript to more than one journal. They also prohibit duplicate publication: submitting work that has been published elsewhere, even in a different language or journal, without clear disclosure. 

Salami slicing (dividing a single study into multiple manuscripts to maximise publication count) is similarly prohibited. Most ICMJE-aligned journals use similarity detection software, and the consequences of detected duplicate submission range from immediate rejection to permanent banning.

Fabrication and Falsification

Research misconduct at the level of data fabrication (inventing data that was not collected) and falsification (altering or selectively presenting data to misrepresent findings) is outside the scope of editorial guidance and into the domain of institutional investigation and legal consequence. ICMJE guidelines require that authors confirm the integrity of the data reported. Journals increasingly require access to raw data during peer review, and image integrity checking is now standard at many leading journals.

Predatory Journals and Publication Ethics

ICMJE membership or endorsement of ICMJE recommendations is a basic quality signal in distinguishing legitimate journals from predatory publications. Predatory journals exploit open-access publication fees without providing genuine peer review, editorial standards, or indexing. Researchers are advised to check whether a target journal is indexed in MEDLINE (accessible via PubMed), whether it is listed in the Directory of Open Access Journals (DOAJ), and whether it is a member of COPE (Committee on Publication Ethics).

Understanding the ethical landscape of medical publishing is inseparable from producing a manuscript that survives peer review. Researchers preparing manuscripts for the first time, or resubmitting after rejection, often benefit from research paper editing that addresses not only language quality but the structural completeness of ethical statements, disclosures, and compliance declarations.

How to Format Clinical Trial Data for Journal Submission

Formatting clinical trial data correctly is a multi-layered task that spans statistical reporting, table construction, figure design, and supplementary material organisation. ICMJE guidelines, in combination with reporting guidelines such as CONSORT, set the framework; journal-specific author instructions set additional requirements.

Statistical Reporting Requirements

The ICMJE recommends that:

• Primary and secondary outcomes be pre-specified in the Methods section and in the clinical trial registration record
• Effect sizes be presented with 95% confidence intervals, not p-values alone
• The statistical significance threshold (alpha level) be stated in the Methods section
• All p-values be reported to at least two significant figures; p-values below 0.001 should be reported as “p < 0.001” rather than exact values
• Baseline characteristics tables present continuous variables as mean (SD) or median (IQR) depending on distribution, with the appropriate test stated
• Subgroup analyses that were not pre-specified be clearly identified as post-hoc or exploratory
• Number needed to treat (NNT) or number needed to harm (NNH) be reported for clinically relevant outcomes in therapeutic trials

Table Formatting for Clinical Trial Data

A well-formatted clinical trial data table should include:

Supplementary Materials

ICMJE and most major journals permit supplementary materials for information that is important but not central to the main findings: extended methods descriptions, sensitivity analyses, additional tables and figures, and the full statistical analysis plan. Supplementary materials must be cited in the main text and submitted in an accessible format. They are typically peer-reviewed alongside the main manuscript.

Researchers who need their clinical trial manuscript structured, formatted, and aligned with CONSORT and ICMJE requirements before submission will find that specialist medical editing and writing support addresses these layers in a single review, reducing the risk of revision requests that delay publication.

ICMJE Clinical Trial Registration

Since 2005, the ICMJE has required that all clinical trials be registered before enrolment in a publicly accessible primary registry that is a member of, or complies with the criteria of, the WHO International Clinical Trials Registry Platform (ICTRP). The ICMJE will not consider for publication any clinical trial that was not prospectively registered.

Qualifying Registries

The registration record must be completed before the first participant is enrolled. It must include the study hypothesis, outcome measures, eligibility criteria, interventions, and the data sharing plan. Amendments to the protocol after registration must be documented in the registry record. The trial registration number must appear in the abstract of the manuscript.

For researchers unsure whether their study qualifies as a “clinical trial” for registration purposes, the ICMJE defines a clinical trial as any research project that prospectively assigns people or a group of people to an intervention, with or without concurrent comparison or control groups, to study the relationship between a health-related intervention and a health outcome. This definition is deliberately broad and includes behavioural, surgical, device, and educational interventions, not only drug trials.

Peer Review, Confidentiality, and Corresponding Author Responsibilities

ICMJE guidelines address the obligations of peer reviewers, editors, and authors during the peer review process. For corresponding authors, the responsibilities extend beyond writing the manuscript.

Corresponding Author Duties

• Be the primary point of contact with the journal throughout submission, peer review, revision, and post-publication
• Ensure all co-authors have approved the final version before submission
• Manage the collection and submission of completed ICMJE conflict of interest disclosure forms for all authors
• Ensure all required statements (ethics, data sharing, clinical trial registration, funding, author contributions) are complete and accurate
• Respond to post-publication correspondence, including requests for data, protocol queries, and corrections
• Notify the journal if errors are identified after publication

Peer Reviewer Obligations Under ICMJE

ICMJE guidelines set clear expectations for peer reviewers: manuscripts must be treated as confidential documents, reviewer comments must be constructive and focused on the scientific merit of the work, and reviewers must declare any conflicts of interest with the authors or content of the manuscript. Using generative AI tools to conduct peer review is prohibited by ICMJE-aligned journals because it shares an unpublished manuscript with a third-party system, violating confidentiality.

For researchers preparing manuscripts that need to be submission-ready before the corresponding author submits to a target journal, professional journal selection and submission support can help identify the correct journal for the study design, impact factor requirements, and submission portal requirements alongside manuscript preparation.

Common ICMJE Compliance Mistakes and How to Avoid Them

The most frequent ICMJE compliance failures that lead to desk rejection or major revision at leading biomedical journals involve a predictable set of errors. Awareness of these errors reduces the revision burden before submission.

ICMJE Compliance Checklist for Medical Authors

Use this checklist before submitting any manuscript to an ICMJE-aligned journal:

• Authorship: All named authors meet all four ICMJE criteria
• CRediT: Contributor roles completed for each author
• COI Forms: ICMJE conflict of interest forms completed and collected from all authors
• Ethics: Ethics committee name and reference number stated in Methods; informed consent confirmed
• Clinical trial registration: Trial registration number included in abstract and Methods; registration completed prospectively
• Reporting guideline: Appropriate checklist (CONSORT, PRISMA, STROBE, etc.) completed and submitted
• CONSORT flow diagram: Prepared and submitted as a figure (for RCTs)
• IMRAD structure: Manuscript follows Introduction, Methods, Results, Discussion structure
• Data sharing statement: Present and complete with all required elements
• References: NLM/Vancouver style; DOIs included; all cited; no fabricated references
• SI units: Used throughout; non-SI units provided with SI equivalents in parentheses
• Acknowledgements: All non-author contributors named; funding sources disclosed
• Cover letter: Confirms no simultaneous submission; addresses journal-specific requirements
• AI use (if applicable): Disclosed in Methods or Acknowledgements with specific tool, purpose, and author verification statement

Researchers who have worked on improving their academic writing style will recognise that ICMJE compliance builds on, but goes beyond, general academic writing quality. The fundamentals of strong academic writing apply throughout every section of a medical manuscript, and mastering them reduces the language-related revision burden alongside technical compliance.

Frequently Asked Questions

What does ICMJE stand for and wh5665o runs it?

ICMJE stands for the International Committee of Medical Journal Editors. It is an informal group of editors from leading biomedical journals, including the New England Journal of Medicine, The Lancet, JAMA, and BMJ, among others. It is not a regulatory body; it operates by consensus and publishes recommendations that journals voluntarily adopt. There is no formal membership fee or application process for journals choosing to align with ICMJE recommendations.

Do I need to cite ICMJE guidelines in my manuscript?

Not typically in the manuscript body itself, but the Methods section should state which reporting guideline was followed (e.g., “This trial is reported in accordance with the CONSORT statement”). For authorship or ethical statements, journals usually want the information presented directly (e.g., the COI disclosure, the ethics approval statement) rather than a citation to the ICMJE document itself. Check your target journal’s specific author instructions.

What happens if a clinical trial was not registered before enrolment?

The ICMJE will not consider for publication any clinical trial that was not prospectively registered. If a trial was inadvertently not registered before enrolment began, some journals may consider publication if registration was completed before data analysis, but this is at editorial discretion and is not guaranteed. Retrospective registration is not an acceptable substitute for prospective registration under ICMJE policy. This makes pre-enrolment registration one of the most consequential compliance steps a clinical researcher must take.

How many authors can a medical manuscript have?

The ICMJE does not set a numerical limit on the number of authors. However, every author must meet all four authorship criteria. Large multicentre trials sometimes use a group authorship model (e.g., “The ADVANCE Collaborative Group”), in which individual contributors are listed in the acknowledgements or in an appendix, with a specified list of individuals who meet full authorship criteria. Journals may have their own guidelines on group authorship formats.

Can a professional medical writer be a co-author?

Yes, if the medical writer meets all four ICMJE authorship criteria. If they contributed substantially to the conception or design of the research, or to the analysis or interpretation of data, drafted or critically revised the manuscript, approved the final version, and agree to be accountable for the work, they qualify as an author. If their contribution was only to drafting or language improvement without intellectual contribution to the study design or interpretation, they should be acknowledged in the Acknowledgements section rather than listed as an author. GPP4 provides additional guidance on how professional medical writers should be acknowledged in industry-sponsored research.

What is the difference between ICMJE authorship criteria and CRediT?

ICMJE authorship criteria determine who qualifies as an author on a manuscript. CRediT (Contributor Roles Taxonomy) is a system for documenting what each qualifying author specifically contributed. They are complementary: ICMJE criteria set the threshold for authorship, and CRediT records how each author’s contribution is categorised. Journals that use CRediT require authors to assign one or more of the 14 defined roles to each named author; this does not change who qualifies for authorship under ICMJE rules.

Is ICMJE compliance required for open access journals?

ICMJE recommendations apply equally to subscription journals and open access journals. Open access journals that are indexed in MEDLINE, listed in DOAJ, and are members of COPE typically align with ICMJE recommendations. Predatory open access journals may claim ICMJE alignment without genuinely implementing the requirements. Researchers submitting to open access outlets should verify journal credibility through MEDLINE indexing and COPE membership before submission.

How should AI writing tools be disclosed under ICMJE guidelines?

ICMJE does not permit AI tools to be listed as authors. Use of AI tools in preparing a manuscript must be disclosed in either the Methods section (if AI was used for data analysis, literature synthesis, or content generation) or the Acknowledgements section (if used for language editing). The disclosure must name the specific tool, describe its use, and confirm that all AI-generated or AI-modified content was reviewed and verified by the authors. The authors remain fully responsible for the accuracy and integrity of the submitted work. This has become a standard check at ICMJE-aligned journals since 2023.

What is the Vancouver reference style and is it the same as NLM format?

Vancouver style and NLM (National Library of Medicine) format refer to the same citation system, named after the 1978 Vancouver meeting at which the ICMJE was established. It uses numbered citations in the order of first appearance in the text, with the reference list structured according to NLM conventions. The NLM style guide is the authoritative reference; PubMed’s citation export format provides Vancouver-style references that can be used directly, though these should always be checked for completeness and accuracy.

How does ICMJE handle corrections and retractions?

The ICMJE recommends that journals publish corrections (errata) for errors that do not affect the validity of the study findings, and retractions for errors that affect the reliability or integrity of the findings, or for cases of research misconduct. Authors who identify errors after publication have an obligation to notify the journal promptly. Retractions must clearly state the reason for retraction and must be indexed in databases alongside the original article. Post-publication corrections are increasingly visible in databases such as PubMed, which links correction notices and retraction statements to original articles.

Achieve ICMJE Compliance with Confidence 

ICMJE medical writing guidelines represent the most widely adopted ethical and structural framework for biomedical publishing in the world. For researchers who want their manuscripts accepted by leading journals, ICMJE compliance is not optional; it is the baseline that peer reviewers and editors check before evaluating the scientific content of a paper. 

Authorship that meets all four criteria, transparent disclosure of conflicts and funding, prospective clinical trial registration, correct use of reporting guidelines including CONSORT, rigorous data sharing statements, and honest ethical declarations are the foundations on which credible medical research publications are built.

Whether you are submitting a randomised controlled trial to a high-impact clinical journal, preparing a systematic review for a specialist publication, or polishing a case report for a society journal, the principles in this guide give you the framework to approach that submission with confidence. 

If you have a manuscript that needs a final expert review before it goes to the journal, Scientific Proofreading UK is here to help.